Cherokee Nation Health Services HCV Elimination Program

Slides:



Advertisements
Similar presentations
DOTS/ DOTS PLUS IMPLEMENTATION AND INTEGRATION Vaira Leimane State Centre of Tuberculosis and Lung Diseases of Latvia Paris, October, 28.
Advertisements

Continuum of Care: Stroke Healthy Population At-Risk Population Stroke Event EMS Emergency Department HospitalRehabilitation.
Arthur Bankhurst, MD Professor of Rheumatology
2.11 Conduct Medication Management University Medical Center Health System Lubbock, TX Jason Mills, PharmD, RPh Assistant Director of Pharmacy.
SDPI Competitive Grant Program Planning Meeting 1 IHS Diabetes Competitive Grant Program: Overview and Update Kelly Acton, MD, MPH, FACP Director, IHS.
Hepatitis and Liver Cancer A National Strategy for Prevention and Control of Hepatitis B and C.
Decision Support for Quality Improvement
Consent2Share Linking Cohort Discovery to Consent David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and.
Informing Public Policy to Address Health Care Disparities Boisey Barnes, MD, F.A.C.C. Founding Member and Trustee Association of Black Cardiologists.
Lauren Lewis, MD, MPH Health Studies Branch Environmental Hazards and Health Effects National Center for Environmental Health Centers for Disease Control.
American Recovery and Reinvestment Act: Summary of Health-related Provisions April 15, 2009.
VETERANS HEALTH ADMINISTRATION Future of HIV in VA Office of Public Health Department of Veterans Affairs Maggie Czarnogorski, MD Deputy Director, HIV,
National Strategy for Quality Improvement in Health Care June 15, 2011 Kana Enomoto Director Office of Policy, Planning, and Innovation.
Hepatitis C: The Silent Epidemic Wednesday, October 21, 2015 John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention.
Hepatitis C RSP Guidance 2016/17 In 2015/16, implementation began on a revised approach to the delivery of hepatitis C services Resources directed towards.
Bringing Hepatitis C Treatment into the Medical Home A Pilot Program for Drug Users Dr. Joanna Eveland MS, MD, Clinical Chief for Special Populations Mission.
S L I D E 0 Enhanced Uptake of Hepatitis C Treatment in an Opioid Treatment Program in the Direct Acting Antiviral Era Jenna Butner MD 1,2, Julia Shi MD.
Lessons Learned and Novel Investigation Techniques in Response to a Large Community Outbreak of HIV-1 infection Philip J. Peters MD HIV Testing and Biomedical.
Florida Cancer Plan Phil Roland, MD FACS FACOG Florida State Chair A Commission on Cancer.
Innovative Strategies for Addressing Hepatitis C in Indian Country March 14, 2016.
Federal Welcome: A View from the Office of HIV/AIDS and
HCV Elimination Is it possible?.
Name(s) Here Job Title(s) Here.
Nurse Managed 12 week Latent Tuberculosis Infection Treatment
Where Are We on the Path to Elimination of Chronic Hepatitis C?
Hepatitis C Virus Program in Chicago
State Office of AIDS Update
Addressing the Behavioral Health Needs of Cook County Residents
Addressing Viral Hepatitis
Cherokee Nation HCV Program: From Evaluation to Cure to Elimination
Precision Medicine, Community Engagement, and Native Health
Addressing the Intersection of Substance Abuse and Viral Hepatitis
NYHQ DSRIP Primary Care & Behavioral Health Committee Kick-Off Meeting
STOP CHLAMYDIA PROGRAM
North Carolina Forum on Sustainable In-Home Asthma Management
Hepatitis C Coordinator IHS National Epidemiology Program
Using Electronic Health Records to Increase Early Cancer Detection
Hepatitis C Incidence and Prevalence in the U.S.
No one gets left behind: Addressing the hidden burden of hepatitis C related advanced liver disease in PWID in the community John S Lambert, MD, PhD.
Hepatitis B and C management pathways in prison:
A qualitative assessment of factors impacting adoption and implementation of USPSTF age-based hepatitis C virus screening recommendations Amy B. Jessop,
The CARE Initiative New Positives Known Positives
Building a Data Driven HCV Screening and Linkage-to-Care Program
Establishing a Pharmacy Managed HCV Service
Chronic Hepatitis C Virus Infection
Jonathan Mermin, MD, MPH RADM, USPHS
Starting Strong: Initial Evaluation of the Patient With HCV
Hepatitis C Screening Best Practices Jenitza Serrano-Feliciano M.D
Expanding the Universe of Viral Hepatitis Treaters
Building Health Systems to Deliver People-centered Health Services
MDHHS Response to the Opioid Crisis
National Programme for limiting spread of HIV/AIDS in Latvia 2008–2012
HBV Care Models: Community Collaborations for Best Practices
What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?
Northwest Tribal Epidemiology Center
Community Advocacy for HCV: Identify, Link to Care, and Treat to Prevent.
Women’s Health Care and Education Coalition
ENDING THE EPIDEMICS: A FOCUS ON PEOPLE WHO INJECT DRUGS
Division of Viral Hepatitis, CDC
Blood borne viral hepatitis action in Wales
Optum’s Role in Mycare Ohio
From ProTEST to Nationwide Implementation
Professor Jack Lambert
Dr Ruitai Shao Programme Management Adviser
Lesson 3: Treatment as Prevention
Human Dignity and Harm Reduction
National Immunization Conference
Lesson 3: The HCV Care Continuum
Hepatitis C case-finding – An opportunity for community pharmacy
March 8, 2006 New ACIP Hepatitis B Recommendations
Presentation transcript:

Cherokee Nation Health Services HCV Elimination Program Jorge Mera, MD, FACP Director, Infectious Diseases Cherokee Nation Health Services

Outline Overview of Cherokee Nation Health Services (CNHS) Chronology of events leading to the HCV elimination program HCV elimination program Goals Progress to date Challenges

Cherokee Nation Jurisdiction Sovereign Nation within a Nation Oklahoma Second largest Indian Nation 322,855 Registered citizens) Medically serves 131,000 AI/AN 14 county area (over 9,200 sq mi.) Capital located in Tahlequah, OK AI/AN: American Indians/ Alaskan Natives

CNHS HCV Program: Chronology 2012 263 patients HCV seropositive CDC recommends Birth Cohort screening 2013 232 patients evaluated (29 treated) Partnered with IHS Birth Cohort HCV electronic health record (EHR) implemented Partnered with UNM ECHO HCV Clinic ECHO: Extended Community Health Outcomes. IHS: Indian Health Services. UNM: Univ. of New Mexico

CNHS HCV Program: Chronology 2014 761 HCV (+) patients (92 treated) Partnered with OUHSC, OSHD, Yale University Estimated 5.8 % HCV prevalence 2015 945 HCV (+) patients (274 treated) 4 CN HCV ECHO clinics Partnered with CDC Elimination Program started (10/2015) HCV Clinic OSHD: Oklahoma State Health Dep. OUHSC: Oklahoma Univ. Health Sciences Center

Birth Cohort HCV Screening in CNHS Percentage of patients in the birth cohort screened who accessed the CN primary care clinics without a previous HCV screen Birth Cohort defined as those patieets born between 1945 and 1965

Birth Cohort HCV Screening CNHS HCV Screening Policy and EHR Reminder HCV Screening Education EHR: Electronoc Health Record

HCV: Age Distribution n=263 Patients who were evaluated for treatment at CNHS (2012) CNHS: Cherokee Nation Healht Services

Linkage to HCV Care and Treatment New DAAs Engagement of PCPs and Pharmacists ECHO DAAs DAA: Direct Antiviral Agents PCP: Primary Care Providers, ECHO: Extended Community Health Outcomes

October 30th CN HCV Awareness Day Goal # 1 Political Commitment October 30th CN HCV Awareness Day

Goal # 2: Expand Screening Program Expand age targeted screening to 20-69 years old Screen 85 % of targeted age group who access the CNHS Serotest 84,000 patients in 3 years HCV screening will be triggered by EHR reminder Lab triggered HCV screening Dental Screening May capture a different population Potentially easier to engage in care

HCV “Lab Triggered” Screening WW Hastings Hospital

Goal #3: Establish Robust Program to link to care, treat and cure patients with HCV Linkage to care, evaluation and treatment Centralized screening reporting and linkage to care Expand use of HCV rapid screening tests Expand local ECHO 20 primary care providers and 8 pharmacists recruited Expand case manager workforce Goals Treat 85% (2,486) of patients with active HCV infection in 3 years (based on an estimated prevalence of 3.7 %) Cure 85% (2,113) of treated patients defined by SVR12

Goal #4: Reduce the incidence of new HCV infections in CNHS Develop and conduct culturally-competent public awareness of risk factors for transmission Treatment as Prevention Contact tracing Nested case control study of acute hepatitis C cases approved by IRB Opioid Substitution programs Naltrexone program in development Needle Exchange programs Discussions ongoing with legislature

Goal #5: Model Elimination of HCV infection in the CNHS Model of HCV transmission dynamics specific to the CN Nested case-control study data , cross-sectional study data and clinical data will be used to model HCV transmission dynamics in CN An advisory committee was established and will assist in development and ongoing review of short and long term goals towards HCV elimination in the CNHS

Challenges Screening EHR reminders are not” pop ups” they require a “reminder for the reminder” Not all patients access the system where screening is offered People who do not access the care system don’t get screened Engangement in care and followup are still a problem Treatment Antivirals procurement is complex Treatment failures are more frequent in the real world Difficult to reach/treat populations PWID/incarcerated people/Homeless/People with alcohol abuse Political Needle exchange prorgrams Funding

Challenges Screening Most EHR reminders are not” pop ups” they may still require a “reminder for the reminder” Not all patients access the system where screening is offered ((Pharmacy, optometry, etc.) Duplicate screening occurs when EHR’s don’t comumicate People who do not access the care system don’t get screened Engangement in care and followup are still a problem Treatment Antivirals procurement is complex Treatment failures are more frequent in the real world Difficult to reach/treat populations PWID/incarcerated people/Homeless/People with alcohol abuse Political Needle exchange prorgrams Funding